Please login to the form below

Not currently logged in
Email:
Password:

New CEO for Merck Serono

Belén Garijo replaces Stefan Oschmann, who moves into a wider group role

Merck Serono Belen Garijo

Merck KGaA has announced several senior personnel changes at its pharma division Merck Serono.

The changes are led by former Merck Serono chief operating officer Belén Garijo's (pictured) appointment as president and CEO.

She replaces Stefan Oschmann who is to focus on a wider group role as a member of the board and head of pharmaceuticals at Merck, developing the business of Merck Serono, Merck's consumer health and biosimilar businesses and the immunotherapy subsidiary Allergopharma.

Oschmann commented that the changes are part of Merck's restructuring plans announced two years ago, which include the loss of thousands of jobs and the closure of its headquarters in Geneva, Switzerland.

He said: “I'm absolutely convinced that with today's management and organisational changes we will be able to fully leverage the growth potential in our pharmaceutical businesses by focusing on fast-growing areas such as the emerging markets and the global allergy market or the rapidly evolving biosimilars market.”

Garijo joined Merck Serono as chief operating officer in 2011. She had previously served as senior VP, global operations region Europe at Sanofi.

During her time at Sanofi, she also took on the role of global integration leader for the company's acquisition of the biotech Genzyme.

Other changes announced by Merck include the appointment of Dr Annalisa Jenkins as head of global research and development. She was previously head of global development and medical.

The company also named Thierry Hulot as head of biosimilars on an interim basis following Jim Stewart's promotion to chief information officer.

30th September 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....